Back to Results
First PageMeta Content
Lipid storage disorders / Lysosomal storage diseases / Glycogen storage disease type II / Fabry disease / Enzyme replacement therapy / Amicus / Mucopolysaccharidosis / Biologic / ERT / Health / Rare diseases / Medicine


Microsoft Word - Broad PR FINAL
Add to Reading List

Document Date: 2013-11-20 18:57:12

Open Document

File Size: 39,82 KB

Share Result on Facebook

Company

Amicus Therapeutics Inc. / Redmile Group / Genzyme / GSK / Callidus Biopharma / Glaxosmithkline plc / /

Country

United States / Canada / /

Currency

USD / /

Event

Funding / Reorganization / M&A / FDA Phase / Conference Call / Business Partnership / Employment Change / Second Stock Issuance / /

Facility

NJ headquarters / /

IndustryTerm

candidate drug products / corporate web site / complimentary enzyme targeting technologies / biopharmaceutical / enzyme targeting technology / Web participants / therapies for rare and orphan diseases / /

MedicalCondition

Pompe disease / orphan diseases / orphan disease / Fabry disease / Parkinson’s disease / lysosomal storage diseases / human genetic diseases / /

MedicalTreatment

Enzyme Replacement Therapies / enzyme replacement therapy / /

Organization

Scientific Advisory Board / /

Person

Hung Do / John F. Crowley / David J. Lockhart / Discovery Biology / /

/

Position

Chairman and Chief Executive Officer / brilliant scientist / great leader / Chief Scientific Officer / Senior Vice President / Private / /

Product

Global / Pompe / Parkinson / AT2220 / /

Technology

alpha / enzyme targeting technology / complimentary enzyme targeting technologies / /

URL

http /

SocialTag